Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Kathryn Deyoung"'
Autor:
Lowell Hart, Augustina Ogbonnaya, Kristen Boykin, Kathryn Deyoung, Ray Bailey, Trevor Heritage, Lorena Lopez‐Gonzalez, Huan Huang, Lucio Gordan
Publikováno v:
Cancer Medicine, Vol 12, Iss 8, Pp 10020-10030 (2023)
Abstract Background Myelosuppression is a major dose‐limiting complication of chemotherapy for patients with extensive‐stage small cell lung cancer (ES‐SCLC). The objective was to describe the burden of myelosuppression, treatment patterns, and
Externí odkaz:
https://doaj.org/article/60e593f5c1924c05bcb67c31cdfa6cbd
Publikováno v:
BMC Pulmonary Medicine, Vol 20, Iss 1, Pp 1-12 (2020)
Abstract Background Pirfenidone and nintedanib are antifibrotic therapies which slow disease progression in idiopathic pulmonary fibrosis (IPF), an irreversible, progressive lung disease with poor prognosis. We compared adherence, persistence, and he
Externí odkaz:
https://doaj.org/article/f613697f517646a79a9ac342d63a7916
Autor:
Anthony N. Sireci, Peter M. Krein, Lisa M. Hess, Taha Khan, Joanne Willey, Michael Ayars, Kathryn Deyoung, Sandhya Bhaskar, Ganiat Mumuney, Anna Coutinho
Publikováno v:
Clinical Lung Cancer.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::04262be0258837466f204dbafae4af49
https://doi.org/10.1016/j.cllc.2023.03.002
https://doi.org/10.1016/j.cllc.2023.03.002
Autor:
Shannon Grogans, Juyoen Hur, Manuel Kuhn, Allegra Anderson, Samiha Islam, Hyung Cho Kim, Rachael Tillman, Andrew Fox, Jason Smith, Kathryn DeYoung, Alexander Shackman
Publikováno v:
Biological Psychiatry. 93:S70-S71
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5d7ba32ff49794977a0e41c7bfc0205d
https://doi.org/10.1016/j.biopsych.2023.02.188
https://doi.org/10.1016/j.biopsych.2023.02.188
Autor:
Shannon Grogans, Juyoen Hur, Matthew Barstead, Allegra Anderson, Samiha Islam, Hyung Cho Kim, Manuel Kuhn, Rachael Tillman, Andrew Fox, Jason Smith, Kathryn DeYoung, Alexander Shackman
Publikováno v:
Biological Psychiatry. 93:S175-S176
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::33a4430caca2cc72532f9c6f3260e6d2
https://doi.org/10.1016/j.biopsych.2023.02.443
https://doi.org/10.1016/j.biopsych.2023.02.443
Autor:
Lowell Hart, Augustina Ogbonnaya, Kristen Boykin, Kathryn Deyoung, Ray Bailey, Trevor Heritage, Lorena Lopez-Gonzalez, Huan Huang, Lucio Gordan
Publikováno v:
International Journal of Cancer Care and Delivery. 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::82c5d9b1a53e43d2a199f44fd6fc285a
https://doi.org/10.53876/001c.38337
https://doi.org/10.53876/001c.38337
Autor:
Deborah A. Fisher, Nicole Princic, A. Burak Ozbay, Lesley Ann Miller-Wilson, Kathleen Wilson, Kathryn DeYoung, Paul J. Limburg
Publikováno v:
International journal of colorectal disease. 37(3)
Purpose This study examined adherence to screening for fecal immunochemical test (FIT). Methods Adults (≥ 50–75) with a FIT between 1/1/2014 and 6/30/2019 in MarketScan administrative claims were selected (index = earliest FIT). Patients were fol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::263898fbb99939168c114d3d0945d773
https://pubmed.ncbi.nlm.nih.gov/34729622
https://pubmed.ncbi.nlm.nih.gov/34729622
Publikováno v:
BMC Pulmonary Medicine, Vol 20, Iss 1, Pp 1-12 (2020)
BMC Pulmonary Medicine
BMC Pulmonary Medicine
Background Pirfenidone and nintedanib are antifibrotic therapies which slow disease progression in idiopathic pulmonary fibrosis (IPF), an irreversible, progressive lung disease with poor prognosis. We compared adherence, persistence, and healthcare
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f48b2d0aebdf6a0d26f60c60bc1eb3a
https://doi.org/10.1186/s12890-020-01224-5
https://doi.org/10.1186/s12890-020-01224-5
Autor:
Pareshkumar Patel, Rodrigo Maegawa, Şerban R. Iorga, Anna D. Coutinho, Xiting Cao, Kathryn Deyoung, Orsolya Lunacsek, Aditya Raju
Publikováno v:
Blood. 138:5036-5036
BACKGROUND: Current treatment guidelines recommend tyrosine kinase inhibitors (TKIs) as first-line and second-line treatment options for patients with chronic myeloid leukemia (CML). 1,2 However, approximately 20% of CML patients fail to respond to t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6b45c6b870a223df24c1bb7b115511b9
https://doi.org/10.1182/blood-2021-152619
https://doi.org/10.1182/blood-2021-152619
Autor:
Kathryn Deyoung, Ganiat Mumuney, Lisa M. Hess, Anthony N. Sireci, Michael Ayars, Taha Khan, Sandya Bhaskhar, Anna D. Coutinho, Peter Mark Krein, Joanne Willey
Publikováno v:
Journal of Clinical Oncology. 39:300-300
300 Background: This study evaluated rates of biomarker testing for patients with stage IV non-squamous NSCLC, which is known to have a ̃40% biomarker-positive rate (AMP, 2020), in a community-based oncology practice setting in the United States (US
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e99602ab8834dfc734f92a3fc26a623d
https://doi.org/10.1200/jco.2020.39.28_suppl.300
https://doi.org/10.1200/jco.2020.39.28_suppl.300